Topic

Nuvalent

A collection of 2 issues

H.C. Wainwright Rates Nuvalent as a Buy with $110 Target

H.C. Wainwright initiates coverage on Nuvalent (NUVL) with a Buy rating and $110 price target, highlighting its potential in lung cancer treatment innovation.

H.C. Wainwright Rates Nuvalent 'Buy' with $110 Target

H.C. Wainwright initiates coverage on Nuvalent (NUVL) with a 'Buy' rating and $110 price target, highlighting its potential in transforming lung cancer treatment.